Read the latest PD-MitoQUANT-acknowledged publication co-authored by our PIs at CNRS

Congratulations to all authors involved in the latest PD-MitoQUANT-acknowledged publication: Nolwen L. Rey, Luc Bousset, Sonia George, Zachary Madaj, Lindsay Meyerdirk, Emily Schulz, Jennifer A. Steiner, Ronald Melki and Patrik Brundin. PD-MitoQUANT PIs Luc Bousset and Ronald Melki are researchers at the Centre National de la Recherche Scientifique (CNRS). The open access paper entitled: α-Synuclein conformational strains spread, seed and target neuronal cells differentially after injection into the olfactory bulb appears in Acta Neuropathologica Communications (2019) 7:221. The study was published on the 30th of December 2019. Read the paper here.

January 20th, 2020|

Interview with PI Dr Olga Corti, ICM

Olga Corti, PhD is a Research Director at the Institut du Cerveau et de la Moelle épinière (ICM) located in Paris, France. Olga is an expert in the functional analysis of protein products of Parkinson’s genes with a focus on mechanisms of mitochondrial quality control. We asked Olga some questions about her research and ICM’s role within PD-MitoQUANT. Within Parkinson’s research, which cell types and mechanisms are most interesting to you at the moment and why? Parkinson’s disease (PD) is due to the gradual loss of specific neuronal populations, particularly those that produce the neurotransmitter dopamine in a deep structure of the brain called substantia nigra. We still do not understand why these neurons die, and it is essential that we do so if we want to find out how to prevent this degenerative process. Until recently, scientists have only been able to study these neurons post mortem, on brains [...]

December 20th, 2019|

PD-MitoQUANT PIs organise “pHysiopathology of Parkinson’s DisEase” (HOPE) 2020 conference at ICM, Paris

PD-MitoQUANT PIs Drs. Olga Corti, Stéphane Hunot (both based at the ICM) and Luc Bousset (Centre National de la Recherche Scientifique (CNRS)) are on the organizing committee of the 2nd "pHysiopathology of Parkinson's DisEase" (HOPE) conference taking place at the Institut du Cerveau et de la Moelle Epinière (ICM) in Paris from the 29th -31st January 2020.   Following the success of the first edition and the positive feedback from participants regarding the latest scientific advances and the integration of basic research into clinical research, ICM is pleased to invite researchers to take part in this second edition. Topics include the epigenetic and genetic determinants of Parkinson's disease, their molecular mechanisms and their modelling, in order to better understand the pathophysiology of Parkinson's disease and open pre-clinical, clinical and imaging perspectives. In addition, ICM proposes a workshop the first day on two topics that will be discussed during the congress: "Cellular modelling using microfluidic and stem [...]

December 12th, 2019|

Highlights of PD-MitoQUANT Plenary Meeting, November 20/21, 2019

At the sunny coastal town of Herzeliya, Israel, over 35 participants from 8 countries across Europe and Israel gathered for the 2nd plenary meeting of the PD-MitoQUANT IMI Consortium to discuss their latest progress toward investigating the role of mitochondrial dysfunction in Parkinson’s. Hosted by Teva Pharmaceutical Industries, researchers from academia, industry and non-profit organizations presented their progress on developing cellular and animal models of Parkinson’s to investigate the impact of alpha-synuclein fibrils on mitochondrial function.   The emotional opening talks by two Parkinson’s patients from the Patient and Public Involvement team at Parkinson’s UK set the tone for the meeting, describing the challenges of life with Parkinson’s and underscoring the importance of an outlook toward patient benefit even in early-stage research. Common themes for debate were the best approaches to model the multi-year, progressive degenerative process of Parkinson’s within the limits of the laboratory setting, the role of non-neuronal cells [...]

November 28th, 2019|